Biogen stock

BIIB · NASDAQ · USD

$253.40Change from previous close: +1.17%Absolute change: +$2.92

Close · November 13, 2026

Price history

+53.83% over the period

1 year: from $164.73 (November 13, 2025) to $253.40 (November 13, 2026), +53.83%.

Show chart data

Closing prices adjusted for splits: the last close of each month.

DateClose
November 13, 2026$253.40
October 30, 2026$253.62
September 30, 2026$225.88
August 31, 2026$216.65
July 31, 2026$202.95
June 30, 2026$216.06
May 29, 2026$196.00
April 30, 2026$189.28
March 31, 2026$183.33
February 27, 2026$191.82
January 30, 2026$179.89
December 31, 2025$175.99
November 28, 2025$182.09
November 13, 2025$164.73

At a glance

  • The company

    Discovers, develops, manufactures and delivers therapies for multiple sclerosis, neurological disorders, cancer, immunology and other conditions

  • Latest results

    Quarter to September 30, 2026 · EPS $2.62 (estimate $2.02)

TickerLandia's take on Biogen

Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks

Where the price stands

52-wk low$160.36
52-wk high$261.00

−2.91% from the 52-week high

Analysts · 36 analysts

Average target$268.26+5.86% vs. price

Buy 25 · Hold 10 · Sell 1 · Buy

TickerLandia Fingerprint: Biogen

Compared with similar companies: very strong momentum.

Financials and price compared with 25 companies in the drug manufacturers - general industry, worldwide. Momentum and risk compared with 883 North American stocks.

Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 16, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated

Valuation

Biogen is pricier than in the past and pricier than similar companies

On the latest fiscal year's earnings (2025), Biogen's P/E today is 28.8, above the median of its last 10 fiscal years (15.3; between 9.44 and 32.5 from 2016 to 2025). Biogen's P/E (trailing 12 months): 108.3, +156% against the median of a group of 10 similar companies (42.3).

P/E compared with its history

Compared with 10 similar companies

Biogen's metrics compared with similar companies
MetricBiogenPosition in the groupBand
P/E (trailing 12 months)108.3High
Forward P/E15.6Low
Operating margin23.5%Low
ROE1.9%Low
Debt/equity0.41Low

P/E at fiscal year end; today on the latest fiscal year's earnings. Grey band: the middle half of the group; tick: the median; dot: Biogen. All multiples and dividends

TickerLandia analysisHow it is calculated

The financials

The business in numbers

Revenue

$2.74B

Latest quarter · Q2 2026

Net income

$97.5M

Latest quarter · Q2 2026

Quarterly net margin

3.6%

Latest quarter · Q2 2026

Numbers and valuation

Full valuation
Market cap
$37.46B
P/E
108.3
EPS
$2.34
Volume
1.03M
Daily trading
€277.08M

How Biogen is changing

All results
  • Revenue fell 6.0% a year on average over the last 5 years

  • Profits turn into cash: free cash flow equal to 148% of net income

  • Shares outstanding down 8.8% in 5 years

Returns

Biogen returns with dividends

$1,000 invested in Biogen 5 years ago, on November 15, 2021, would be worth $932 today with dividends reinvested: −6.78% in total, −1.40% per year. On price alone it would be $932 (−6.78%).

PeriodBiogenS&P 500$1,000 becomes
1 month+10.70%−3.12%$1,107
6 months+23.89%+1.58%$1,239
Year to date+43.99%+10.46%$1,440
1 year+53.83%+12.23%$1,538
3 years+13.84%+71.41%$1,138
5 years−6.78%+61.48%$932
10 years−14.55%+249.40%$855

Over the last 6 months it has done better than 60% of the stocks in the Healthcare sector.

From 1 year up with dividends reinvested, before taxes; under a year price only. S&P 500: price only. Calculate your investment

The chart in detail

Biogen: technical analysis

Biogen is in an uptrend: the price is above its 50- and 200-session moving averages, and the 200-session average is rising. The price is 46.8% below its all-time closing high ($475.98, March 20, 2015).

Trend
Upward
RSI (14 sessions)
59
Between 30 and 70
vs 200-session average
+23.52%

Support and resistance

Price areas where Biogen has stopped several times in the last year. They describe the chart; they are not forecasts.

  1. No resistance above: the price is near the highs of the year
  2. Last price$253.40
  3. Support$224.33−11.47%2 touches, last on September 3, 2026
  4. Support$217.46−14.18%4 touches, last on October 8, 2026
  5. Support$207.45−18.13%2 touches, last on September 10, 2026

Volatility and risk

Over the last year it has moved less than the S&P 500.

Beta (1 year) vs S&P 500
0.42
Volatility (60 sessions, annualised)
28.2%
Largest fall in the last year
−14.34%

Close of November 13, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it

Biogen: seasonality

Average monthly price change over 36 years

+3.9%Jan−0.3%Feb−2.4%Mar−2.0%Apr+3.4%May+1.9%Jun+3.2%Jul+3.2%Aug+2.4%Sep+6.1%Oct+1.8%Nov+3.4%Dec

Over the last 36 years, the strongest month for Biogen has been October: +6.06% on average, positive in 20 years out of 36. The weakest has been March: −2.40% on average, positive in 16 years out of 35. November, the current month, has been positive in 21 years out of 35 (+1.82% on average).

Show chart data
MonthAverageMedianPositive years
January+3.93%+2.22%20 of 35
February−0.28%−1.73%15 of 35
March−2.40%−0.19%16 of 35
April−1.96%−1.62%12 of 35
May+3.35%+3.55%22 of 35
June+1.90%−0.66%17 of 35
July+3.20%+2.67%23 of 35
August+3.18%+2.84%21 of 35
September+2.37%+0.64%18 of 35
October+6.06%+4.24%20 of 36
November+1.82%+3.37%21 of 35
December+3.42%−1.12%16 of 35

Price change only, dividends excluded. Past seasonality does not predict future moves.

The company

Biogen and its competitors

Biogen's sales reach across the United States, Europe, Germany, Asia and other international markets, where it discovers, develops, manufactures and delivers therapies. Its portfolio centres on treatments for multiple sclerosis, including TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and OCREVUS, alongside SPINRAZA for spinal muscular atrophy, SKYCLARYS for Friedreich's Ataxia, QALSODY for amyotrophic lateral sclerosis and LEQEMBI for Alzheimer's disease. The company also sells biosimilars of ENBREL, HUMIRA and REMICADE, anti-CD20 lymphoma and leukemia therapies such as RITUXAN and GAZYVA, and ZURZUVAE for postpartum depression.

Headquarters
Cambridge, United States
Employees
7,500
Founded
1978
Chief executive
Christopher Viehbacher
Biogen and its competitors
CompanyMarket capOperating marginP/E (trailing 12 months)6 months
BiogenBIIB$37.46B23.5%108.3+23.89%
Bristol-Myers SquibbBMY$129.66B32.4%14.1+12.48%
PfizerPFE$164.67B29.1%41.3+11.29%
Gilead SciencesGILD$208.48B38.2%—+26.33%
AmgenAMGN$251.89B34.1%27.0+38.41%
MerckMRK$364.26B35.2%147.8+30.24%

Same industry or related industries, similar size. Compare Biogen with its competitors · Full profile